英文名稱 | Lenacapavir |GS-6207 |
---|---|
中文名稱 | 來那卡帕韋 |
CAS號(hào) | 2189684-44-2 |
分子式 | C39H32ClF10N7O5S2 |
分子量 | 968.28 |
外觀 | White to light yellow powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 | |
---|---|---|---|---|---|
暫無牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。 |
英文名稱 | Lenacapavir |GS-6207 |
---|---|
中文名稱 | 來那卡帕韋 |
CAS號(hào) | 2189684-44-2 |
分子式 | C39H32ClF10N7O5S2 |
分子量 | 968.28 |
外觀 | White to light yellow powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Lenacapavir (GS-6207) is a novel, first-in-class,long-acting and highly potent HIV-1 capsid inhibitor approved in EU on August 22, 2022 to treat HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis.